Do analysts prefer BNR or KMDA?

Kamada has a consensus price target of $13.50, indicating a potential upside of 52.54%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kamada 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer BNR or KMDA?

In the previous week, Kamada had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 7 mentions for Kamada and 1 mentions for Burning Rock Biotech. Kamada's average media sentiment score of 0.56 beat Burning Rock Biotech's score of 0.00 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PBYI or BNR?

Puma Biotechnology presently has a consensus target price of $6.00, indicating a potential downside of 37.50%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Puma Biotechnology is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PBYI or BNR?

In the previous week, Puma Biotechnology had 8 more articles in the media than Burning Rock Biotech. MarketBeat recorded 9 mentions for Puma Biotechnology and 1 mentions for Burning Rock Biotech. Puma Biotechnology's average media sentiment score of 0.48 beat Burning Rock Biotech's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PRTA or BNR?

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 186.38%. Given Prothena's stronger consensus rating and higher possible upside, research analysts clearly believe Prothena is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PRTA or BNR?

In the previous week, Prothena and Prothena both had 1 articles in the media. Prothena's average media sentiment score of 1.08 beat Burning Rock Biotech's score of 0.00 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BNR or KYTX?

Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 320.76%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Does the media refer more to BNR or KYTX?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Kyverna Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Kyverna Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BNR or AGMB?

AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 208.13%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88

Which has better valuation & earnings, BNR or AGMB?

Burning Rock Biotech has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Burning Rock Biotech $77.16M 1.94 -$7.92M -$0.87 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media favor BNR or AGMB?

In the previous week, AgomAb Therapeutics had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 7 mentions for AgomAb Therapeutics and 1 mentions for Burning Rock Biotech. AgomAb Therapeutics' average media sentiment score of 0.48 beat Burning Rock Biotech's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Burning Rock Biotech (BNR) Competitors

$14.23 +0.71 (+5.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.90 +0.67 (+4.74%)

As of 09/18/2026 07:30 PM Eastern

Compare

BNR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include Kamada (KMDA), Puma Biotechnology (PBYI), Prothena (PRTA), Kyverna Therapeutics (KYTX), and AgomAb Therapeutics (AGMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Kamada?

Burning Rock Biotech (NASDAQ:BNR) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Kamada has a net margin of 11.60% compared to Burning Rock Biotech's net margin of -13.60%. Kamada's return on equity of 8.37% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Kamada	11.60%	8.37%	5.85%

Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Kamada has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Kamada had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 7 mentions for Kamada and 1 mentions for Burning Rock Biotech. Kamada's average media sentiment score of 0.56 beat Burning Rock Biotech's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

Kamada has a consensus price target of $13.50, indicating a potential upside of 52.54%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Burning Rock Biotech on 14 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

In the previous week, Puma Biotechnology had 8 more articles in the media than Burning Rock Biotech. MarketBeat recorded 9 mentions for Puma Biotechnology and 1 mentions for Burning Rock Biotech. Puma Biotechnology's average media sentiment score of 0.48 beat Burning Rock Biotech's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.17	$31.11M	$0.52	18.46
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A

Puma Biotechnology has a net margin of 11.50% compared to Burning Rock Biotech's net margin of -13.60%. Puma Biotechnology's return on equity of 20.76% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Puma Biotechnology presently has a consensus target price of $6.00, indicating a potential downside of 37.50%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Puma Biotechnology is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Puma Biotechnology beats Burning Rock Biotech on 13 of the 15 factors compared between the two stocks.

How does Burning Rock Biotech compare to Prothena?

Prothena (NASDAQ:PRTA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 186.38%. Given Prothena's stronger consensus rating and higher possible upside, research analysts clearly believe Prothena is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Prothena has a beta of -0.33, suggesting that its share price is 133% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Burning Rock Biotech has a net margin of -13.60% compared to Prothena's net margin of -80.68%. Burning Rock Biotech's return on equity of -12.98% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Burning Rock Biotech has higher revenue and earnings than Prothena. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.40	-$244.09M	-$0.84	N/A
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A

In the previous week, Prothena and Prothena both had 1 articles in the media. Prothena's average media sentiment score of 1.08 beat Burning Rock Biotech's score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.1% of Prothena shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Prothena beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Kyverna Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 320.76%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Burning Rock Biotech has higher revenue and earnings than Kyverna Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Kyverna Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Kyverna Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Burning Rock Biotech and Kyverna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Burning Rock Biotech compare to AgomAb Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Burning Rock Biotech has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 208.13%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

AgomAb Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. AgomAb Therapeutics' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
AgomAb Therapeutics	N/A	N/A	N/A

30.0% of Burning Rock Biotech shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 7 mentions for AgomAb Therapeutics and 1 mentions for Burning Rock Biotech. AgomAb Therapeutics' average media sentiment score of 0.48 beat Burning Rock Biotech's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AgomAb Therapeutics beats Burning Rock Biotech on 8 of the 12 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$149.72M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-16.36	14.23	274.93	25.38
Price / Sales	1.94	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.95	15.45	10.46	6.33
Net Income	-$7.92M	-$22.86M	$3.49B	$358.33M
7 Day Performance	15.88%	-1.21%	0.59%	1.12%
1 Month Performance	40.97%	-4.42%	-2.01%	-2.67%
1 Year Performance	66.12%	37.81%	18.09%	6.01%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	0.6291 of 5 stars	$14.23 +5.3%	N/A	+71.3%	$149.72M	$77.16M	N/A	667
KMDA Kamada	4.9687 of 5 stars	$8.09 -2.6%	$13.00 +60.7%	+27.3%	$477.87M	$191.85M	21.29	462	News Coverage Analyst Forecast
PBYI Puma Biotechnology	1.0985 of 5 stars	$9.25 +1.2%	$6.00 -35.1%	+112.4%	$471.81M	$228.40M	17.79	179	News Coverage Insider Trade
PRTA Prothena	3.3567 of 5 stars	$8.33 -6.0%	$24.57 +195.0%	+4.9%	$463.85M	$54.53M	N/A	67	News Coverage
KYTX Kyverna Therapeutics	1.449 of 5 stars	$6.96 -5.9%	$30.00 +331.0%	+42.3%	$457.64M	N/A	N/A	149

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

How does Burning Rock Biotech compare to Kamada?

Summary

How does Burning Rock Biotech compare to Puma Biotechnology?

Summary

How does Burning Rock Biotech compare to Prothena?

Summary

How does Burning Rock Biotech compare to Kyverna Therapeutics?

Summary

How does Burning Rock Biotech compare to AgomAb Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

How does Burning Rock Biotech compare to Kamada?

Is BNR or KMDA more profitable?

Which has more risk & volatility, BNR or KMDA?

Do insiders and institutionals believe in BNR or KMDA?

Does the media prefer BNR or KMDA?

Which has higher valuation & earnings, BNR or KMDA?

Do analysts prefer BNR or KMDA?

Summary

How does Burning Rock Biotech compare to Puma Biotechnology?

Does the media prefer PBYI or BNR?

Which has preferable valuation and earnings, PBYI or BNR?

Is PBYI or BNR more profitable?

Do analysts rate PBYI or BNR?

Which has more volatility & risk, PBYI or BNR?

Do insiders & institutionals believe in PBYI or BNR?

Summary

How does Burning Rock Biotech compare to Prothena?

Do analysts recommend PRTA or BNR?

Which has more risk & volatility, PRTA or BNR?

Is PRTA or BNR more profitable?

Which has better valuation and earnings, PRTA or BNR?

Does the media refer more to PRTA or BNR?

Do insiders & institutionals hold more shares of PRTA or BNR?

Summary

How does Burning Rock Biotech compare to Kyverna Therapeutics?

Do analysts recommend BNR or KYTX?

Do institutionals & insiders believe in BNR or KYTX?

Which has more risk and volatility, BNR or KYTX?

Is BNR or KYTX more profitable?

Which has preferable valuation and earnings, BNR or KYTX?

Does the media refer more to BNR or KYTX?

Summary

How does Burning Rock Biotech compare to AgomAb Therapeutics?

Which has better valuation & earnings, BNR or AGMB?

Do analysts recommend BNR or AGMB?

Is BNR or AGMB more profitable?

Do insiders and institutionals believe in BNR or AGMB?

Does the media favor BNR or AGMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools